Sophora flavescens and lavender flavones and application thereof

Abstract

The invention relates to the technical field of medicines, in particular to sophora flavescens and lavender flavones and application thereof. The lavender flavone component group prepared from a radix sophorae flavescentis medicinal material has obvious activity of inhibiting propionibacterium acnes, staphylococcus epidermidis and staphylococcus aureus and melanin inhibition activity, is high in purity and few in impurities, can be widely applied to medicines or health-care foods for preventing and treating human hyperpigmentation diseases or acne dermatitis, and has a wide application prospect. The traditional Chinese medicine composition has the advantages of obvious curative effect, small toxic and side effects, good safety, high druggability and good medicinal prospect, and can be taken for a long time.

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, and particularly to sophora flavescens lavender flavonoids and their uses. Background Art

[0002] Sophora flavescens is the dried root of the leguminous plant Sophora flavescens Alt., which is one of the traditional Chinese medicines commonly used in China and also one of the commonly used raw materials for cosmetics. It has the effects of clearing heat and drying dampness, killing insects, and promoting diuresis. It is mainly used for treating dysentery, hematochezia, jaundice with oliguria, leukorrhea, etc. It contains alkaloids, flavonoids, phenylpropanoids, dibenzoyl derivatives, terpenoids, steroids, organic acids, fatty acids, volatile oils and other components, among which alkaloids and flavonoids are its main active components. Modern pharmacological studies have shown that sophora flavescens has pharmacological effects such as anti-tumor, anti-inflammatory, analgesic, and antibacterial. Early studies on the chemical constituents of sophora flavescens mainly focused on alkaloid components, while recent studies have mostly concentrated on the flavonoid compounds it contains. Relevant studies have shown that sophora flavescens flavonoids have various pharmacological activities such as antibacterial, antioxidant, and anti-tumor. Therefore, the present invention further studies the extracts or active ingredients of sophora flavescens to find its new action targets in order to develop valuable drugs. Summary of the Invention

[0003] In order to overcome the above technical defects, the present invention uses a simple process to prepare a high-purity lavender flavonoid component group from sophora flavescens medicinal materials, and conducts relevant pharmacodynamic and pharmacological studies on lavender flavonoids and their corresponding pharmaceutical preparations. The results show that the lavender flavonoids prepared by the present invention have obvious antibacterial activity and melanin inhibitory activity, with significant efficacy, low toxicity and side effects, and high safety, and can be applied to the fields of food, cosmetics, medicine, etc.

[0004] One of the purposes of the present invention is to provide sophora flavescens lavender flavonoids, which are extracted by the following method:

[0005] S1. Extract sophora flavescens with methanol to make a concentrated solution;

[0006] S2. Extract the concentrated solution with ethyl acetate, separate the ethyl acetate phase, and make an extract;

[0007] S3. Mix the extract with silica gel and load it onto a column, perform silica gel column chromatography separation, elute successively with petroleum ether and ethyl acetate, collect the ethyl acetate eluate, and concentrate it under reduced pressure to make an extract, thus obtaining the product.

[0008] Further, in S1, the methanol is a 60-100% methanol aqueous solution;

[0009] And / or, in S1, the dosage of methanol is 8-12 times the amount of sophora flavescens;

[0010] And / or, in S1, the extraction process is reflux extraction for 1-5 h;

[0011] And / or, in S1, the extraction process is repeated 1 - 5 times, and the filtrates are combined to prepare a concentrated solution.

[0012] Further, in S2, before the extraction of the concentrated solution, the pH value is adjusted to 1 - 2.

[0013] And / or, in S2, the concentrated solution is repeatedly extracted with ethyl acetate until there is no flavonoid in the aqueous phase, and the ethyl acetate phases are combined.

[0014] Further, in S3, for the silica gel column after adsorption, it is first eluted with petroleum ether for 5 column volumes, and then eluted with ethyl acetate. After TLC detection until there is no flavonoid reaction, the ethyl acetate eluate is collected and concentrated under reduced pressure to prepare an extract.

[0015] The second object of the present invention is to provide a method for preparing sophora flavescens and lavender flavonoids, comprising the following steps: S1. Extract sophora flavescens with methanol to prepare a concentrated solution.

[0016] S2. Extract the concentrated solution with ethyl acetate, separate the ethyl acetate phase, and prepare an extract.

[0017] S3. The extract is loaded onto a silica gel column after mixing with silica gel, and silica gel column chromatography separation is carried out. It is eluted successively with petroleum ether and ethyl acetate, the ethyl acetate eluate is collected, and concentrated under reduced pressure to prepare an extract, thus obtaining the product.

[0018] In some specific embodiments, in S1, the methanol is a 60 - 100% methanol aqueous solution.

[0019] In some specific embodiments, in S1, the dosage of the methanol is 8 - 12 times the amount of sophora flavescens.

[0020] In some specific embodiments, in S1, the extraction process is reflux extraction for 1 - 5 h.

[0021] In some specific embodiments, in S1, the extraction process is repeated 1 - 5 times, and the filtrates are combined to prepare a concentrated solution.

[0022] In some specific embodiments, in S2, before the extraction of the concentrated solution, the pH value is adjusted to 1 - 2.

[0023] In some specific embodiments, in S2, the concentrated solution is repeatedly extracted with ethyl acetate until there is no flavonoid in the aqueous phase, and the ethyl acetate phases are combined.

[0024] In some specific embodiments, in S3, for the silica gel column after adsorption, it is first eluted with petroleum ether for 5 column volumes, and then eluted with ethyl acetate. After TLC detection until there is no flavonoid reaction, the ethyl acetate eluate is collected and concentrated under reduced pressure to prepare an extract.

[0025] A third object of the present invention is to provide the use of sophora flavescens lavender flavonoids in the preparation of a drug for preventing and / or treating dermatitis.

[0026] The drug is used to inhibit one or more of Propionibacterium acnes, Staphylococcus epidermidis, and Staphylococcus aureus.

[0027] The drug according to the present invention may be composed of sophora flavescens lavender flavonoids and a pharmaceutically acceptable carrier.

[0028] By using the methods of the prior art, the drug can be processed into forms such as tablets, capsules, pills, powders, granules, syrups, solutions, emulsions, injections, sprays, aerosols, and patches.

[0029] In particular, the pharmaceutically acceptable carrier is generally recognized for this purpose and serves as an inactive ingredient of the medicament.

[0030] The carrier includes excipients such as starch, water, etc.; lubricants such as magnesium stearate, etc.; disintegrants such as microcrystalline cellulose, etc.; fillers such as lactose, etc.; binders such as pregelatinized starch, dextrin, etc.; sweeteners; antioxidants; preservatives; flavoring agents; fragrances, etc.

[0031] Among them, the drug is administered through gastrointestinal and non-gastrointestinal routes.

[0032] In particular, the non-gastrointestinal administration route is selected from injection administration, respiratory administration, skin administration, mucosal administration, or cavity administration.

[0033] Among them, non-gastrointestinal administration preparations are selected from injections, sprays, aerosols, patches, etc.

[0034] In particular, the gastrointestinal administration preparations are selected from tablets, capsules, powders, granules, pills, solutions, emulsions, or syrups, etc.

[0035] Another object of the present invention is to provide a drug for preventing and / or treating dermatitis, which contains sophora flavescens lavender flavonoids or other components with anti-inflammatory activity for compound use.

[0036] Another object of the present invention is to provide a method for preventing, alleviating, and treating dermatitis, which includes administering a therapeutically effective amount of sophora flavescens lavender flavonoids to a patient.

[0037] A fourth object of the present invention is to provide the use of sophora flavescens lavender flavonoids in the preparation of a whitening drug.

[0038] The drug is used to prevent and treat human pigmentation diseases or melanoma diseases caused by abnormal melanin.

[0039] The drug according to the present invention may consist of sophora flavescens lavender flavonoids and a pharmaceutically acceptable carrier.

[0040] Using the methods of the prior art, the drug can be processed into forms such as tablets, capsules, pills, powders, granules, syrups, solutions, emulsions, injections, sprays, aerosols, and patches.

[0041] In particular, the pharmaceutically acceptable carrier is generally recognized for this purpose and serves as an inactive ingredient of the medicament.

[0042] The carrier includes excipients such as starch, water, etc.; lubricants such as magnesium stearate, etc.; disintegrants such as microcrystalline cellulose, etc.; fillers such as lactose, etc.; binders such as pregelatinized starch, dextrin, etc.; sweeteners; antioxidants; preservatives; flavoring agents; fragrances, etc.

[0043] Among them, the drug is administered through enteral and parenteral administration routes.

[0044] In particular, the parenteral administration routes are selected from injection administration, respiratory administration, skin administration, mucosal administration, or cavity administration.

[0045] Among them, parenteral administration preparations are selected from injections, sprays, aerosols, patches, etc.

[0046] In particular, the enteral administration preparations are selected from tablets, capsules, powders, granules, pills, solutions, emulsions, or syrups, etc.

[0047] Another object of the present invention is to provide a whitening drug, which contains sophora flavescens lavender flavonoids, or other components with tyrosinase inhibitory activity are used in combination.

[0048] Another object of the present invention is to provide a method for whitening, preventing and treating human pigmentation diseases or melanoma diseases caused by abnormal melanin, which includes administering a therapeutically effective amount of sophora flavescens lavender flavonoids to a patient.

[0049] Those skilled in the art can understand that the dosage of the pharmaceutical composition of the present invention depends on many factors, such as the gender, age, weight and individual response of the patient or animal, the administration route and the number of administrations, etc. The above dosage can be administered in a single dosage form or divided into several, such as two, three or four dosage forms. The dosage level must be selected according to the specific administration route, the severity of the condition to be treated, and the condition and medical history of the patient to be treated, etc. However, the practice in the art is to start with a dosage lower than the level required to obtain the desired therapeutic effect and gradually increase the dosage until the desired effect is obtained.

[0050] Unless otherwise specified, the term "therapeutically effective amount" as used herein refers to the amount of a drug required to produce an effective effect; the "therapeutically effective amount" can be adjusted and varied and is ultimately determined by medical personnel, taking into account factors such as the route of administration and the nature of the formulation, the general conditions of the recipient such as body weight and age, and the nature and severity of the disease being treated.

[0051] The sophora flavescens lavender flavonoid prepared from sophora flavescens herbs in the present invention has obvious activities of inhibiting Propionibacterium acnes, Staphylococcus epidermidis, Staphylococcus aureus and melanin inhibition. Moreover, it has high purity and few impurities, and can be widely applied to drugs or health foods for preventing and treating human pigmentation diseases or acne dermatitis. It has remarkable curative effects, small toxic and side effects, good safety, can be taken for a long time, and has high drug-likeness and good medicinal prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 It is the bacteriostatic activity diagram of sophora flavescens lavender flavonoid of the present invention;

[0053] Among them, 1a is the test result diagram of Propionibacterium acnes bacteriostatic test; 1b is the test result diagram of Staphylococcus epidermidis bacteriostatic test; 1c is the test result diagram of Staphylococcus aureus bacteriostatic test;

[0054] Figure 2 It is the growth inhibition rate diagram of different bacteria;

[0055] Figure 3 It is the diagram of the influence of the present invention on the scratching times of the dermatitis-like mouse model; *P<0.05, **P<0.01,

[0056] ***P<0.001 vs. model group; #P<0.05, ##P<0.01, P<0.001 vs. normal group;

[0057] Figure 4 It is the influence of the present invention on the organs of the dermatitis-like mouse model;

[0058] Among them, 4a is the influence on the spleen index; 4b is the influence on the thymus index;

[0059] Figure 5 It is the diagram of the influence of the present invention on the ear thickness measurement of the dermatitis-like mouse model; *P<0.05, **P<0.01, ***P<0.001 vs. model group; #P<0.05, ##P<0.01, P<0.001 vs. normal group;

[0060] Figure 6Effect diagram of the present invention on the clinical skin lesion score of a dermatitis-like mouse model; *P<0.05, **P<0.01, ***P<0.001 vs. model group; #P<0.05, ##P<0.01, P<0.001 vs. normal group; ns, no significant difference compared with the model group;

[0061] Figure 7 Effect diagram of sophora flavescens lavender flavonoids on the melanin in the head of zebrafish;

[0062] Figure 8 Effect of sophora flavescens lavender flavonoids on melanin density. Detailed implementation manners

[0063] To enable those skilled in the art to better understand the technical solution of the present invention, the present invention will be described in detail below in combination with the specific implementation manners. The experimental methods without specific conditions noted in the following examples are usually in accordance with conventional conditions or the conditions recommended by the manufacturer. The test materials used in the following examples are all obtained from a conventional biochemical reagent store without special instructions. Unless otherwise stated, percentages and parts are calculated by weight. Unless otherwise defined, all professional and scientific terms used herein have the same meaning as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to the described content can be applied to the present invention. The preferred implementation methods and materials described herein are for illustrative purposes only.

[0064] In the ranges disclosed herein, the endpoints and any values are not limited to the exact ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, between the endpoint values of each range and individual point values, and between individual point values can be combined with each other to obtain one or more new numerical ranges, and these numerical ranges should be regarded as specifically disclosed herein.

[0065] The technical solution of the present invention will be further described in detail below in combination with specific examples and attached tables. It should be understood that the following examples are only used to explain the present invention and are not used to limit the present invention.

[0066] Example 1 Preparation of sophora flavescens lavender flavonoids

[0067] Take Sophora flavescens, crush it, and extract it with 80% methanol reflux, with a solid-liquid ratio of 1:10, and extract it 3 times, each time for 2 hours. Combine the extracts and concentrate until there is no alcohol taste; take the concentrate, adjust the pH value to 1-2 with hydrochloric acid, extract it with ethyl acetate, monitor the extraction with thin layer until there is no flavonoid reaction, and combine the ethyl acetate layer; after concentrating the ethyl acetate layer, mix the sample with a small amount of silica gel to prepare the column, first use petroleum ether to elute 5 column volumes, then elute with ethyl acetate, monitor the elution with thin layer until there is no flavonoid reaction, collect the ethyl acetate part, concentrate it, and obtain it. The purity of lavender flavonoids in the extract was 68.33% detected by aluminum nitrate colorimetry (detection wavelength 500nm).

[0068] Example 2 Investigation of the antibacterial activity of lavender flavonoids from Sophora flavescens

[0069] Cell lines: Propionibacterium acnes (ATCC11827), Staphylococcus epidermidis (ATCC 12228), and Staphylococcus aureus (ATCC 6538) were obtained from the Microbial Culture Collection Center of Guangdong Institute of Microbiology;

[0070] Experimental samples: Propylene glycol, pionin, mupirocin ointment

[0071] Experimental instruments: Bacterial incubator (Jintan City Jerrell Electric Company, MJ-150B), multifunctional microplate reader (Beckman DTX 800, USA), anaerobic culture bag (Mitsubishi Lijiu Chemical Co., Ltd., Japan)

[0072] (1) Paper disc method: The liquid prepared by Sophora flavescens lavender flavonoids, propylene glycol, and pionin prepared in Example 1 was soaked in a 6 mm paper disc, and the test bacteria were plated at 6.0×108 CFU / mL, and the paper disc was pasted on an agar plate. Propionibacterium acnes was placed in an anaerobic culture box and incubated at 37°C for 48 hours, and Staphylococcus epidermidis and Staphylococcus aureus were placed in a 37°C incubator and incubated for 24 hours. The size of the inhibition zone was observed and measured. The experiment was repeated 3 times. The test results are shown in Table 1 and Figure 1 shown.

[0073] Table 1 Inhibition zone of each tested bacteria (mm)

[0074]

[0075] From Table 1 and Figure 1 As shown, Propionibacterium acnes is highly sensitive to the flavonoids of Sophora flavescens, and there is no inhibition zone for propylene glycol and piorning samples; Staphylococcus epidermidis is highly sensitive to the flavonoids of Sophora flavescens, and is lowly sensitive to the piorning sample, and there is no inhibition zone for the propylene glycol sample; Staphylococcus aureus is moderately sensitive to the flavonoids of Sophora flavescens, and is lowly sensitive to the piorning sample, and there is no inhibition zone for the propylene glycol sample. This shows that Sophora flavescens lavender flavonoids has significant inhibitory activity against Propionibacterium acnes, Staphylococcus epidermidis, and Staphylococcus aureus, especially the strongest inhibitory effect on Propionibacterium acnes.

[0076] (2) Colorimetric method: The liquid medicines prepared from sophora flavescens-lavender flavonoids, propylene glycol, and piroctone obtained in Example 1 were respectively added to a 96-well plate, and then 180 μl of the bacterial suspension was added; the blank group was 200 μl of blank liquid medium; the control group was 200 μl of bacterial liquid. Propionibacterium acnes was incubated in an anaerobic culture box in a constant temperature incubator at 37 °C for 48 h, and Staphylococcus epidermidis and Staphylococcus aureus were incubated in a constant temperature incubator at 37 °C for 24 h. The OD value at 600 nm was measured by an enzyme-linked immunosorbent assay (ELISA) reader. The growth inhibition rate was calculated according to the following method: Growth inhibition rate = (OD of the control group - OD of the experimental group) / (OD of the control group - OD of the blank group). The experiment was repeated 3 times, and the test results are as Figure 2 shown.

[0077] As can be seen from Figure 2 it, sophora flavescens-lavender flavonoids, propylene glycol, and piroctone samples all have inhibitory effects on Propionibacterium acnes, Staphylococcus epidermidis, and Staphylococcus aureus, and sophora flavescens-lavender flavonoids have the strongest activity.

[0078] Example 3 investigated the alleviating effect of sophora flavescens-lavender flavonoids on MC903-induced dermatitis in mice

[0079] Animal administration and grouping: 170 healthy SPF-grade male BALB / c mice, 6 - 8 weeks old, with a body weight of (20 ± 2) g. After one week of adaptive feeding, they were raised in a specific pathogen-free environment with air flow, a temperature of (23 ± 2) °C, a humidity of (55 ± 5)%, and a 12-hour light-dark cycle, and were allowed to eat and drink freely. After one week of adaptive feeding of the experimental animals, they were randomly divided into 17 groups of 10 mice each. Every morning, 20 μL / mouse of 2 nmol MC903 solution was evenly applied to the right ears of the model group and each administration group, and 20 μL of absolute ethanol was applied to the left ears as a solvent control. The blank group was applied with an equal amount of absolute ethanol for 10 consecutive days. From the fourth day, the corresponding drugs were applied topically at 20 μL / mouse. The administrations of each group are shown in Table 2:

[0080] Table 2

[0081]

[0082]

[0083] (1) Effect on the scratching times of the MC903-induced dermatitis-like mouse model

[0084] Each group of mice was observed behaviorally for 15 min (observation), and the latency period and the number of scratching times within 15 min were recorded. If it was continuous scratching, it was only counted as 1 time. The test results are shown in Figure 3 .

[0085] As Figure 3As shown, compared with the normal group, the scratching times in the model group were significantly increased. Compared with the model group, the positive drug and the other administration groups could all reduce the scratching times of mice to varying degrees, and the total flavonoids of Sophora flavescens group had the most obvious effect.

[0086] (2) Effects on the organ coefficients of MC903-induced dermatitis-like mouse models

[0087] On the last day of the experiment, the body weights were recorded. The animals were anesthetized with 1% sodium pentobarbital solution. After collecting blood from the abdominal aorta, the spleen and thymus were dissected, the wet weights of the organs were weighed, and the organ coefficients were calculated. Organ coefficient = organ mass (mg) / body weight (g). The test results are shown in Figure 4 .

[0088] As Figure 4 shown in a, compared with the normal group, the spleen index in the model group decreased slightly. Compared with the model group, there were no significant differences in the other administration groups; as Figure 4 shown in b, compared with the model group, there were significant differences in the dexamethasone acetate group (Dex.), high-dose total alkaloids of Sophora flavescens group (KSZJJ-H), medium-dose total alkaloids of Sophora flavescens group (KSZJJ-M), medium-dose matrine monomer group (DGY-M), and low-dose matrine monomer group (DGY-L), indicating that total alkaloids of Sophora flavescens and matrine monomer may have inhibitory toxicity to the thymus.

[0089] (3) Effects on the ear thickness measurement of MC903-induced dermatitis-like mouse models

[0090] On the 0th, 2nd, 4th, 6th, 8th, and 10th days after modeling, the thickness changes of the same parts of the left and right ears of the mice in each group were measured three times respectively. The final result was the average value of the three numerical values, and the ear swelling thickness (mm) was calculated. Swelling degree (mm) = right ear thickness - left ear thickness.

[0091] As Figure 5 shown, except for the normal group, the ear thickness of the other groups showed an upward trend, and the model group was more obvious. Compared with the normal group, the ear thickness in the model group increased significantly, with significant differences and statistical significance. Compared with the model group, each administration group could reduce the ear swelling degree of mice to varying degrees, and the inhibitory activity of the high-dose total flavonoids of Sophora flavescens was the strongest.

[0092] (4) Effects on the clinical skin lesion scores of MC903-induced dermatitis-like mouse models

[0093] Clinical skin lesion scores were performed according to Table 3 on the 0th day and the 10th day of the experiment.

[0094] Table 3

[0095] Degree of skin lesion Erythema (hemorrhage) Edema (papule) Epidermal exfoliation (scratch) Scale (dryness) None (0 point) None None None None Mild (1 point) Vaguely visible, pink Almost imperceptible elevation above the skin surface A little superficial epidermal exfoliation Bran-like desquamation Moderate (2 points) Clearly visible, dark red Clearly visible elevation above the skin surface, but not significant <![CDATA[Many superficial and / or some deeper epidermal exfoliations]]> Thin flaky scales covering thinly Severe (3 points) Dark red or fiery red Significantly elevated above the skin surface <![CDATA[Diffuse superficial and / or many deep epidermal desquamations]]> Covered with thick scales

[0096] As Figure 6As shown, compared with the normal group, the ears of the mice in the model group were significantly swollen and red, accompanied by some scales. The clinical skin lesion score was significantly increased, showing a significant difference and statistical significance. Compared with the model group, after topical administration, except for the low-dose group of total matrine, the low- and medium-dose groups of matrine monomer, and the low-dose group of Kushen extract pills, the redness and scaling of the mice's ears were alleviated in the remaining groups, showing statistical significance, and the high-dose group of total flavonoids of Sophora flavescens had the strongest efficacy.

[0097] Example 4 investigated the inhibitory activity of Kushen Lavender flavonoids on melanin

[0098] Experimental reagents: water (deionized water or water of the same purity); dimethyl sulfoxide; nicotinamide; sodium bicarbonate; potassium chloride; calcium chloride dihydrate; magnesium sulfate heptahydrate.

[0099] Experimental instruments: stereomicroscope; electronic balance; constant temperature incubator; and other conventional laboratory instruments and equipment: such as pipettes, volumetric flasks, beakers, aluminum foil, pipettes, etc.

[0100] Select 6hpf wild-type AB strain zebrafish into 6-well plates and randomly divide them into 6 groups: normal group (no treatment), positive group (0.2% nicotinamide), DMSO group (0.1% DMSO), experimental groups 1-3 (Kushen Lavender flavonoids (KSHT) prepared in Example 1 were respectively made into concentrations of 2.5 μg / mL, 10 μg / mL, and 20 μg / mL) for the experiment, and incubated at 28 °C for 45 h; randomly select 10 zebrafish from each group to take pictures of the zebrafish heads under a dissection microscope and save the pictures, and use ImageJ software to analyze the relative area of melanin in the zebrafish heads and calculate the total relative density value. The test results are as Figures 7 - 8 shown.

[0101] As Figure 7 shown, compared with the normal control group, the melanin in the heads of zebrafish in the experimental groups of Kushen Lavender flavonoids at different concentrations decreased, revealing that this sample has a whitening effect; as Figure 8 shown, compared with the normal group, Kushen Lavender flavonoids significantly reduced the density of melanin in the concentration range of 2.5 - 20 μg / mL.

[0102] Finally, it should be noted that the above description is only the preferred embodiment of the present invention. Those skilled in the art, under the inspiration of the present invention and without violating the purpose and claims of the present invention, can make various similar representations, and such transformations all fall within the protection scope of the present invention.

Claims

1. Sophora flavescens lavender flavonoids, characterized in that, The extraction was performed using the following method: S1. extracting Sophora flavescens with methanol to prepare a concentrated solution; S2. extracting the concentrate with ethyl acetate, separating the ethyl acetate phase, and preparing an extract; S3. The extract is mixed with a sample and loaded onto a silica gel column for silica gel column chromatography separation. It is eluted with petroleum ether and ethyl acetate in sequence. The ethyl acetate eluate is collected and concentrated under reduced pressure to obtain the extract.

2. The sophora flavescens lavender flavonoids according to claim 1, characterized in that In S1, the methanol is a 60-100% methanol aqueous solution; And / or, in S1, the amount of methanol is 8-12 times the amount of Sophora flavescens; And / or, in S1, the extraction process is reflux extraction for 1-5h; And / or, in S1, the extraction process is repeated 1-5 times, and the filtrates are combined to prepare a concentrated solution.

3. The sophora flavescens lavender flavonoids according to claim 1, characterized in that In S2, before the concentrated solution is extracted, the pH value is adjusted to 1-2; And / or, in S2, the concentrated solution is repeatedly extracted with ethyl acetate until no flavonoids are left in the aqueous phase, and the ethyl acetate phases are combined.

4. The sophora flavescens lavender flavonoids according to claim 1, characterized in that In the S3, the silica gel column after adsorption is first eluted with petroleum ether for 5 times the column volume, and then eluted with ethyl acetate, and detected by TLC until no flavonoids react, the ethyl acetate eluate is collected, and concentrated under reduced pressure to prepare an extract.

5. The method for preparing the lavender flavonoids of any one of claims 1 to 4, characterized in that: The following steps are involved: S1. extracting Sophora flavescens with methanol to prepare a concentrated solution; S2. extracting the concentrate with ethyl acetate, separating the ethyl acetate phase, and preparing an extract; S3. The extract is mixed with a sample and loaded onto a silica gel column for silica gel column chromatography separation. It is eluted with petroleum ether and ethyl acetate in sequence. The ethyl acetate eluate is collected and concentrated under reduced pressure to obtain the extract.

6. Use of the Sophora flavescens lavender flavonoids according to claims 1-4 in the preparation of a medicament for preventing and / or treating dermatitis.

7. The use according to claim 6, characterized in that: The drug is used for inhibiting one or more of Propionibacterium acnes, Staphylococcus epidermidis and Staphylococcus aureus.

8. Use of the sophora flavescens lavender flavonoids according to claims 1-4 in the preparation of whitening drugs.

9. The use according to claim 6, characterized in that: The drug is used to inhibit tyrosinase.

10. A drug, characterized in that: The invention is prepared by using the sophora flavescens lavender flavonoids described in claims 1 to 4 as active ingredients and adding pharmaceutically acceptable excipients.

Images